Tucked inside a nondescript complex in Arden Hills, Smiths Medical has produced reliable drug pumps and medical devices with stagnant revenue growth that invited years of speculation that the business could be spun off by its London-based owners at any moment.
What a difference 18 months makes.
Smiths Medical has a new CEO, and the company is moving into a shiny world headquarters in Plymouth, where it will spend an enhanced R&D budget. Employees are being encouraged to pursue bolder ideas. And research money is being invested in all four Smiths Medical divisions, instead of mainly in its drug infusion pump business.
Last week, Smiths Medical reported sales of $1.27 billion for the year that ended in July, with 4 percent organic revenue growth — its best showing in nearly a decade.
Smiths Medical was once seen as a prime target to be sold by Smiths Group PLC, the global manufacturing conglomerate that owns it. Two such offers were made public but never executed. Last week, however, analysts noted the revenue growth at Smiths Medical was one of the bright spots in 2015 for Smiths Group, which saw declines in sales of everything from airport security scanners to mechanical seals for oil rigs.
The medical-device division contributed 29 percent of the global conglomerate's revenue.
"This is a very important part of the Smiths portfolio, and we are getting a lot of investment," Smiths Medical CEO Jeff McCaulley said. McCaulley, 49, was hired as CEO of Smiths Medical in March 2014, following executive roles in Medtronic's diabetes business and Zimmer's joint-replacement division.
Asked about the likelihood of a sale of Smiths Medical now, McCaulley was careful to note that no well-performing company can rule out a buyout, especially given the strong appetite for deals among medical technology companies in the past year. But he sees a future in which Smiths Medical is more likely the buyer in M&A deals, rather than the seller.